Ireland· IE-PA-EU/1/25/2011/001-003
Cenrifki 60 mg film-coated tablets
A medicinal product containing tolebrutinib, registered in Ireland by Sanofi Winthrop Industrie.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Tolebrutinib
- Manufacturer
- Sanofi Winthrop Industrie
- Country
- Ireland (IE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/25/2011/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tolebrutinib in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCENRIFKISanofi Winthrop Industrie, Gentilly
- SpainCENRIFKI 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULASanofi Winthrop Industrie
- BelgiumCenrifki 60 mgSanofi Winthrop Industrie
- NetherlandsCenrifki 60 mg filmomhulde tablettenSanofi Winthrop Industrie
- PolandCenrifkiSanofi Winthrop Industrie
- SwedenCenrifki 60 mg Filmdragerad tablettSanofi Winthrop Industrie
- FinlandCenrifkiSanofi Winthrop Industrie
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cenrifki
- Liechtenstein · Cenrifki
- Norway · Cenrifki
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1e358135-b7d0-4d7d-9372-27bc38af7318 GET /v1/drugs/1e358135-b7d0-4d7d-9372-27bc38af7318?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": null,
"strength": null,
"pa_number": "EU/1/25/2011/001-003",
"substances": [
"Tolebrutinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "*** AWAITING VALUE ***",
"registration_status": "AU",
"supply_legal_status": null,
"interchangeable_code": null
}See everything about tolebrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.